Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OS.

13 , 14 , 15 , 16 , 17 , 18 , 19 In this view, in our study, MRD negativity before transplantation showed a trend toward a longer survival (median OS, not reached vs 26 months, in patients with negative or positive pre-HSCT MRD, respectively; P = .06), albeit without reaching statistical significance, probably because of the low number of MRD-positive patients receiving HSCT.

also in 53,322 other papers